NCT06766461View on ClinicalTrials.gov

Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis

PHASE4RecruitingINTERVENTIONAL
Enrollment

980

Participants

Timeline

Start Date

January 3, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions
Sepsis - to Reduce Mortality in the Intensive Care UnitSepsisSeptic Shock
Interventions
DRUG

Double dosing of beta-lactam antibiotic

This arm will receive double dosing of beta-lactam antibiotics for the first 48 hours after inclusion.

Trial Locations (1)

Unknown

RECRUITING

Maasstad Ziekenhuis, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Maasstad Hospital

OTHER

collaborator

Albert Schweitzer Hospital

OTHER

lead

Erasmus Medical Center

OTHER

NCT06766461 - Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis | Biotech Hunter | Biotech Hunter